Testing an antiviral’s effects in early COVID-19
Treatments studied
Part of Infections, Lungs & breathing clinical trials.
This trial looks at how well an antiviral works in the body when started early in people with COVID-19 symptoms. You may be able to join if you’re an otherwise healthy adult with confirmed infection and symptoms for less than 4 days.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must understand the study and sign informed consent
- You’re 18 to 60 years old and otherwise healthy
- You have early COVID-19 symptoms for less than 4 days
- Your COVID test is positive very recently (within 24 hours for PCR) or a positive rapid test
- Your oxygen level is at least 96% at screening and you can walk normally
- You can follow study visits and contact instructions for follow-up
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether PF-07321332 (with ritonavir) helps children under 18 who have COVID-19 at home but are at high risk of severe illness. It looks at whether starting treatment early can reduce progression to worse disease.
This trial tests a new drug, ratutrelvir, for people with mild to moderate COVID-19. It aims to find a safe and effective dose to help you feel better faster.
This trial tests a longer course of remdesivir plus Paxlovid (nirmatrelvir/ritonavir) for immunocompromised people with persistent COVID-19. It aims to see if combining these two antiviral medicines can help clear the virus more effectively.
This trial tests if a 600 mg dose of nitazoxanide (an antiparasitic drug) can help outpatients with early COVID-19 or flu recover more quickly. If you've just tested positive for COVID-19 or influenza and your symptoms started less than 48 hours ago, this study might be for you.
This trial tests whether Codivir can help people hospitalized with moderate COVID-19 recover better than a placebo (inactive pill). It will compare outcomes while participants receive standard hospital care.
This trial tests whether an optimized antiviral treatment can help people with weakened immune systems who have COVID-19. It aims to find the best way to treat them to prevent severe illness.
Hear when a new COVID-19 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.